A meta-analysis of 10 studies involving 1050 patients of European and Asian origin (472 patients with DLBCL and 578 patients with another NHL), investigated a possible association between the FcγRIIIa polymorphism and non-responsiveness to rituximab-based therapy in NHL (17). The gene discussed is FCGR3A; the disease is diffuse large B-cell lymphoma.